Phase 2Status unknownAge-related condition

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease: a Double-blind, Placebo-controlled Prevention Study in Elderly Patients With Mild Cognitive Impairment

Sponsor
University of Sao Paulo (Academic or other)
Enrollment
80 planned
Conditions
Cognitive Impairment; Alzheimer Disease
Interventions
Lithium Carbonate; Placebo
Ages
adults, older adults
Registry
NCT01055392

Full record on ClinicalTrials.gov

From the registry

Lithium salts have been used for the treatment of psychiatric disorders for over five decades, mostly as a mood-stabilizing drug. Recent evidence points to the inhibition of the enzyme glycogen synthase kinase-3beta (GSK3) as one of its mechanisms of action. The overactivity of this enzyme has been implicated in the pathogenesis of Alzheimer's disease (AD), given its involvement in mechanisms related to the hyperphosphorylation of Tau protein and the production of beta-amyloid peptide. These are key events leading respectively to the formation of neurofibrillary tangles and senile plaques, which are the neuropathological hallmarks of the disease. Several in vitro and animal studies have shown that the inhibition of GSK3 by lithium and other agents attenuates these pathological processes, reinforcing the notion that GSK3 is a likely target for future disease-modifying therapies for AD. Indeed, a recent study published by our group showed that chronic lithium use is associated with a decrement in the expected prevalence of dementia, in a sample of elderly individuals with bipolar…

Primary outcomes

  • effect of lithium to delay progression of cognitive deficits in patients with amnestic MCI

History

  1. Registered

  2. Primary completion

  3. Started

Papers citing this trial